检索

A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian

Poddubnaya I., Kolyadina I., Kalashnikov N., Borisov D., Makarova M.

A clinical case of treatment of recurrent inoperable locally advanced breast cancer using conformal radiotherapy. Case report

Medvedev S., Vlasova M., Bolotina L., Kaprin A., Khmelevskiy E., Zikiryakhodzhaev A., Khakimova S., Khakimova G., Bychkova N., Zaitseva N., Abushova E., Guseva S., Maslov E.

(Rus)

Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

Kolyadina I.

(Rus)

卷 26, 编号 3 (2024)

New therapies for hormone-positive HER2-negative metastatic breast cancer with AKT signaling alterations: the Expert Panel Decision

Editorial B.

(Rus)

卷 24, 编号 1 (2022)

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)

Uvarova K.

(Rus)

卷 16, 编号 3 (2014)

Avastin in clinical chemotherapy of malignant tumors

Gorbunova V.

卷 24, 编号 1 (2022)

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

Sokolova T., Solov'eva T., Aleksakhina S., Janus G., Goryainova A., Gluzman M., Orlova R., Stukan A., Zukov R., Zyuzyukina A., Murunova Y., Sultanbaev A., Vorobeva E., Mikhaevich L., Pyliv V., Lysenko A., Khachmamuk Z., Kozlov A., Bakharev S., Parsyan S., Rossokha E., Osidze L., Shumskaya I., Agaeva A., Kasmynina T., Klimenko V., Akhmetgareeva K., Vakhitova A., Chakhkieva M., Dmitriev V., Bakshun Y., Vasilyev A., Gasimly D., Kravchenko N., Maksimov D., Nesterova A., Sharvashidze I., Gadzaova C., Rakhmankulova G., Khamgokov Z., Amirkhanova I., Bembeeva L., Vladimirov V., Petrenko O., Ruskova N., Serikova E., Subbotina K., Tkachenko S., Chang V., Erdniev S., Barbara V., Vasilevskaya A., Mikheeva Y., Popova N., Startseva E., Fateeva A., Yukalchuk D., Grechkina A., Musaeva K., Odintsova S., Stel'makh A., Khabibulaeva P., Khlobystina A., Shvaiko K., Basova E., Bogomolova I., Bolieva M., Goldberg V., Kibisheva M., Menshikov K., Ryazanov D., Stepanova M., Udalova Y., Shkradyuk A., Chapko Y., Shchukina A., Khabriev I., Kirtbaya D., Degtyarev A., Epkhiev A., Tyugina Y., Murachuev M., Togo A., Ievleva A., Imyanitov E.

(Rus)

(Eng)

Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)

Kolyadina I., Poddubnaya I., Van de Velde C., Kuppen P., Frank G., Komov D., Karseladze A., Bastiaannet E., Dekker-Ensink N.

卷 15, 编号 3 (2013)

Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii

Kolyadina I., Poddubnaya I., Trofimova O., Komov D., Karseladze A., Ermilova V., Vishnevskaya Y., Frank G., Banov S.

Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review

Sultanbaev A., Kolyadina I., Gilyazova I., Nasretdinov A., Musin S., Sultanbaeva N., Menshikov K.

(Rus)

卷 27, 编号 1 (2025)

Long-term aesthetic outcomes of reconstructive surgeries with endoprosthetics for breast cancer: A review

Khomidi U., Vlasova M., Saribekyan E., Zikiryakhodzhaev A., Khakimova S., Khakimova G., Kodzoeva D.

(Rus)

卷 27, 编号 2 (2025)

Preclinical studies of cytotoxicity and cytostatic activity of five new imidazotriazine derivatives in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures

Al-Humairi A., Buldakov M., Novochadov V., Cherdyntseva N., Udut V.

(Rus)

卷 27, 编号 2 (2025)

Role of repeat biopsies of metastatic and recurrent lesions for the study of tumor heterogeneity in luminal breast cancer: Retrospective and prospective analyses

Gluzman M., Chistyakova E., Raskin G., Orlova R.

(Rus)

Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review

Kolyadina I.

(Rus)

卷 23, 编号 3 (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

Editorial B.

(Rus)

卷 27, 编号 2 (2025)

Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case

Radyukova I., Rats N.

(Rus)

卷 22, 编号 1 (2020)

Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer

Kolyadina I., Danzanova T., Khokhlova S., Trofimova O., Kovaleva E., Rodionov V., Poddubnaya I.

(Rus)

卷 20, 编号 3 (2018)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer

Kolyadina I., Poddubnaya I.

(Rus)

The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan

Berdimyradova M., Khadjiev S., Khommadova D., Polatova G., Kakajanova A., Batyrov C., Penayev D., Agayeva B., Annaberdiyeva G.

(Rus)

卷 19, 编号 1 (2017)

Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer

Pavlikova O., Kolyadina I., Komov D., Vishnevskaya Y., Poddubnaya I.

(Rus)

卷 18, 编号 1 (2016)

Rare morphological forms of breast cancer: features of surgical approach

Vysotskaya I., Letyagin V., Kolyadina I., Martynova G.

(Rus)

卷 21, 编号 3 (2019)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer

Gordeeva O., Kolyadina I., Zhukova L., Gan'shina I., Komov D., Meshcheriakov A.

(Rus)

卷 15, 编号 2 (2013)

Prognostic value of p53 expression in patients with stage I breast cancer

Kolyadina I., Poddubnaya I., Van de Velde C., Kuppen P., Liefers G., Dekker-Ensink N., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D., Karseladze A., Ermilova V., Vishnevskaya Y., Frank G., Banov S.

卷 18, 编号 2 (2016)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype

Karabina E., Zhukova L.

(Rus)

Influence of radiation therapy on the development of complications in single-stage autologous breast reconstruction with a DIEP-flap in breast cancer patients: a retrospective study

Duadze I., Kaprin A., Zikiryakhodzhaev A., Reshetov I., Usov F., Rasskazova E., Sukhotko A., Starkova M., Bagdasarova D., Dzhabrailova D., Khakimova S.

(Rus)

卷 11, 编号 4 (2009)

Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade

Lichinitser M., Semenov N.

Squamous cell breast cancer: description of a rare clinical case

Zikiryakhodjaev A., Khakimova S., Rasskazova E., Saribekian E., Omarova D., Surkova V., Khakimova G.

(Rus)

Experience in the treatment of radioinduced angiosarcoma of the breast in a patient with primary multiple lesions of the breast and bladder. Case report

Semenov E., Gasymly D., Zyuzyukina A., Zukov R.

(Rus)

The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer

Vashenko L., Daschkova I., Bakulina S., Andreyko E.

Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study

Golubenko E., Savelyeva M., Poddubnaya I., Korennaya V.

(Rus)

卷 19, 编号 2 (2017)

PARP inhibitors in female reproductive system cancers

Pokataev I., Tyulyandin S.

(Rus)

Benefits and limitations of breastfeeding for mothers with malignant tumors

Ladodo O., Iurova M., Khokhlova S., Rodionov V., Sheshko E., Zubkov V., Makieva M., Chutkova D., Akhapkina E., Degtyarev D.

(Rus)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study

Evdokimov V., Bloshchinenko A., Abolmasov A., Vilensky A., Laskov M.

(Rus)

卷 21, 编号 1 (2019)

The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)

Morozov D., Kolyadina I., Poddubnaya I., Chumakov P., Ilinskaya G., Bokhian V., Sopova M.

(Rus)

卷 8, 编号 1 (2006)

Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy

Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study

Zabotina T., Chertkova A., Borunova A., Kushlinskii N., Gershtein E., Zakharova E., Shoua E., Tsiklauri V., Samoylenko I., Khoroshilov M., Kadagidze Z.

(Rus)

卷 24, 编号 2 (2022)

Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

Sultanbaev A., Menshikov K., Musin S., Nasretdinov A., Fatikhova A., Izmailov A., Lipatov O., Ayupov R., Sultanbaeva N., Menshikova I., Serebrennikov G.

(Rus)

Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer

Semiglazova T., Dashyan G., Semiglazov V., Zhabina A., Osipov M., Kotova Z., Klimenko V., Krivorotko P., Semiglazov V.

卷 16, 编号 4 (2014)

Male breast cancer: review of the literature

Nikolaev K., Semiglazov V., Semiglazov V.

The results of Epidemiological HER2 screening program in patients with breast cancer in 2013

Frank G., Poddubnaya I., Yagudina R., Borisov D., Koroleva N.

卷 11, 编号 2 (2009)

Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii

Zavalishina L., Andreeva Y., Ryazantseva A., Bateva M., Frank G.

Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya

Myasnikova M.

卷 27, 编号 1 (2025)

Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review

Grechukhina K., Sukhova M., Kolyago E., Filonenko D., Zhukova L.

(Rus)

Isolated metastasis to the scalp in occult breast cancer: a clinical case

Ognerubov N., Sergeev R., Hizhnyak A., Ognerubova M., Dzhabrailov M.

(Rus)

Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report

Grechukhina K., Vorontsova K., Filonenko D., Tyutyunnik P., Shchadrova V., Zhukova L.

(Rus)

卷 23, 编号 3 (2021)

Can any breast skin thickening be staged as T4?

Amosova V., Petrovskii A., Karpova M., Ponedel’nikova N., Frolova M.

(Rus)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Mazurina N., Artamonova E., Beloyartseva M., Volkova E., Ganshina I., Troshina E., Tjulandin S., Chubenko V.

(Rus)

Opportunities for metastatic triple negative breast cancer therapy

Ganshina I., Gordeeva O., Manukyan M.

(Rus)

卷 19, 编号 2 (2017)

Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?

Trigolosov A., Uimanov V., Chernikh M., Petrovskiy A., Nikitina E., Nechushkin M.

(Rus)

卷 16, 编号 4 (2014)

Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)

Kolyadina I., Poddubnaya I.

Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board

Artamonova E., Gorbunova V., Zhukov N., Manzjuk L., Manihas A., Paltuev P., Semiglazov V., Semiglazova T., Stenina M., Tjuljandin S., Chubenko V.

卷 10, 编号 1 (2008)

Effektivnost' ad\"yuvantnoy terapii anastrozolom i tamoksifenom u patsientok s rannimi stadiyami raka molochnoy zhelezy (analiz dannykh issledovaniya ATAC pri mediane vremeni nablyudeniya 100 mes)

卷 9, 编号 2 (2007)

Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii

Zavalishina L., Andreeva Y., Ryazantseva A., Bateva M., Frank G.

卷 7, 编号 3 (2005)

Sovremennye vozmozhnosti lekarstvennoy terapii operabel'nogo raka molochnoy zhelezy (po materialam St. Gallen, 2005)

Letyagin V., Vysotskaya I.

«Problema optimizatsii ad\"yuvantnoy endokrinnoy terapii na rannikh stadiyakh raka molochnoy zhelezy»

Semiglazov V., Poddubnaya I.

Prognostic significance of androgen receptor expression in triple-negative breast cancer

Panchenko I., Panchenko S., Sharafutdinov M., Rodionov V., Kometova V., Burmenskaya O.

(Rus)

卷 25, 编号 4 (2023)

Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer

Ognerubov N., Barsukov S.

(Rus)

The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review

Grechukhina K., Kalugin M., Prosvirnov A., Sukhova M., Zhukova L.

(Rus)

Antiangiogenic therapy for breast cancer with triple negative phenotype

Ganshina I., Ivanova K., Gordeeva O., Arkhipov A., Zhukova L.

(Rus)

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review

Poddubnaya I., Gligorov J., Zhukova L., Kovalenko E., Frolova M.

(Rus)

Ribociclib in 1st line HR+ breast cancer treatment

Zhukova L., Ganshina I., Gordeeva O., Lubennikova E.

(Rus)

卷 18, 编号 2 (2016)

Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast

Rudakova A., Tolkacheva D., Gavrilova O., Vaganov A.

(Rus)

卷 16, 编号 3 (2014)

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial

Ahmetzanov F., Ahmetzanova F.

卷 16, 编号 1 (2014)

New chemotherapy options for triple-negative breast cancer (review of literature)

Sekundova M., Zdvizhkov A., Borisov V.

卷 11, 编号 1 (2009)

Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin

Borisova E., Voronina I., Gutorov S.

Odnomomentnye mastektomii i laparoskopicheskie ovariektomii v lechenii raka molochnoy zhelezy

Khvastunov R., Kireev A., Nikol'skiy I., Suvorov V.

Opyt primeneniya Regional'noy programmy v g. Krasnodare

Mitashok I.

Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review

Imyanitov E.

(Rus)

卷 24, 编号 1 (2022)

Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence

Editorial B.

(Rus)

卷 23, 编号 4 (2021)

Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021

Editorial B.

(Rus)

Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer

Samaneva N., Vladimirova L., Kolyadina I., Frantsiyants E., Storozhakova A., Bandovkina V., Kalabanova E., Kabanov S., Svetitskaya I., Tishina A., Ezhova M.

(Rus)

Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Frolova M., Kochetkova Y., Chubenko V., Volkov N., Moiseenko F., Garmarnik T., Ponomarenko D., Orlov A., Kostalanova Y., Makarycheva Y., Nizegorodzeva A.

(Rus)

卷 19, 编号 3 (2017)

Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer

Nenakhova Y., Lyadov V., Poddubnaya I.

(Rus)

卷 19, 编号 3 (2017)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving

Artamonova E.

(Rus)

卷 19, 编号 1 (2017)

Albumin-bound paclitaxel in the treatment of metastatic breast cancer

Artamonova E.

(Rus)

The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer

Frolova M.

(Rus)

卷 17, 编号 4 (2015)

Neoadjuvant systemic therapy of HER2-positive breast cancer

Frolova M.

Radiation-induced lung injury in breast cancer patients after breast conservation therapy

Trofimova O., Tkachev S., Ivanov S., Utkina V., Cheban O., Glebovskaya V.

卷 16, 编号 4 (2014)

Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?

Kolyadina I., Poddubnaya I., Trofimova O., Frank G., Karseladze A., Komov D.

Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom

Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards

卷 15, 编号 4 (2013)

The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)

Semiglazov V., Semiglazov V., Paltuev P., Nikolaev K., Dashyan G.

卷 15, 编号 1 (2013)

Current approach to adjuvant therapy for breast cancer (a review)

Conte P., Guarneri V.

卷 11, 编号 3 (2009)

Zhukova L., Abramov M., Vakhabova Y., Lud A., Obukhov A., Lichinitser M.

卷 10, 编号 1 (2008)

Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii

卷 9, 编号 1 (2007)

Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy?

Ptushkin V.

卷 7, 编号 3 (2005)

Aromazin: printsip deystviya

Imyanitov E.

Farmorubitsin v klinicheskoy praktike

Gorbunova V.

Analiz rezul'tatov vnedreniya Regional'noy rossiyskoy programmy lecheniya pervichno-generalizovannogo i metastaticheskogo raka molochnoy zhelezy v Voronezhskom oblastnom klinicheskom onkologicheskom dispansere

Chevardov N., Tolstykh L., Puzakov K., Potapov Y.

Immunological predictors of the therapeutic efficacy of atezolizumab in combination with nab-paclitaxel in metastatic triple-negative breast cancer: A pilot multicenter retrospective associative study

Kalinchuk A., Popova N., Gofman A., Usoltseva I., Perelmuter V., Tashireva L.

(Rus)

Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study

Sultanbaev A., Kolyadina I., Menshikov K., Musin S., Nasretdinov A., Sultanbaeva N., Rakhimov R., Lipatov D., Menshikova I., Izmailov A., Lipatova E.

(Rus)

Relationship of the integrin profile of the primary tumor to metastasis to regional lymph nodes in breast cancer

Zavyalova M., Kuznecov G., Grigoryeva E., Tashireva L., Pismenny D., Perelmuter V.

(Rus)

卷 25, 编号 2 (2023)

Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study

Chulkova S., Sholokhova E., Poddubnaya I., Stilidi I., Burov D., Tupitsyn N.

(Rus)

Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: a regional analysis

Valiachmetova C., Siraev E., Izmailov A.

(Rus)

The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study

Chulkova S., Sholokhova E., Poddubnaya I., Stilidi I., Tupitsyn N.

(Rus)

The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia

Sokolova T., Aleksakhina S., Yanus G., Sultanbaev A., Menshikov K., Lysenko A., Zukov R., Zyuzyukina A., Murunova Y., Rossokha E., Bakharev S., Basova E., Kasmynina T., Shumskaya I., Bakshun Y., Musaeva K., Khasanova A., Dmitriev V., Bolieva M., Gadzaova C., Petrenko O., Maksimov D., Vladimirov V., Goldberg V., Popova N., Kibisheva M., Khamgokov Z., Vasilyev A., Iyevleva A., Imyanitov E.

(Rus)

卷 23, 编号 3 (2021)

The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer

Tabakov D., Zabotina T., Chanturia N., Zakharova E., Vorotnikov I., Selchuk V., Sokolovskiy V., Petrovsky A.

(Rus)

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Zhukova L., Ganshina I., Khatkova E., Tikhomirova T., Kondratyeva O.

(Rus)

卷 19, 编号 4 (2017)

Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case

Kolyadina I., Ganshina I., Zhukova L., Abdullaev A., Andreeva Y., Danzanova T., Sinyukova G., Komov D., Kozlov N., Filonenko D., Gordeeva O., Lubennikova E.

(Rus)

Klinicheskiy sluchay effektivnogo lecheniya lapatinibom (Tayverb)i kapetsitabinom (Kseloda) bol'noy disseminirovannym rakom molochnoy zhelezy s giperekspressiey ErbB2 (Her-2/neu) s metastaticheskim porazheniem veshchestva i obolochek golovnogo mozga

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia

Bolotina L., Manziuk L., Gorbunova V., Kovalenko E., Mukhametshina G., Khasanova A., Vladimirova L., Mitashok I., Prokofyeva E., Evstigneeva I., Andreyashkina I., Abramova N., Popova I., Karabina E., Teterich A., Gaysina E., Chubenko V., Limareva S., Tikhanovskaya N., Storozhakova A., Samaneva N., Svetitskaya Y., Snezhko T., Kalabanova E.

(Rus)

卷 15, 编号 3 (2013)

Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii

Frank G., Poddubnaya I., Yagudina R., Borisov D.

卷 11, 编号 3 (2009)

Naskhletashvili D., Chmutin G.

卷 11, 编号 1 (2009)

Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)

Zhukova L.

卷 10, 编号 2 (2008)

Femara (letrozol) v sovremennoy terapii raka molochnoy zhelezy

Perevodchikova N.

卷 10, 编号 1 (2008)

8 let nadezhdy: novye dannye issledovaniya ATAS

卷 9, 编号 2 (2007)

Primenenie Zomety na fone endokrinnoy terapii Femaroy u bol'nykh rakom molochnoy zhelezy s metastazami v kosti

Konstantinova M., Ovchinnikova L., Lomakin N., Galleev M., Neretina E., Mukhamedshina G., Mukhametgaleeva F.

卷 9, 编号 1 (2007)

Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera)

Shisterova O., Golik E.

Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy

Makarenko N.

Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy

Bozhok A., Semiglazov V., Kletsel' A., Arzumanov A., Ivanova O., Semiglazov V.

The role of ESR1 gene mutation in therapy selection for HR+/HER2- metastatic breast cancer: A review

Paichadze A., Chashnikova E., Golubeva S.

(Rus)

Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study

Zhukova L., Bolotina L., Dvornichenko V., Fadeeva N., Ganshina I., Grechukhina K., Hasanova A., Kislov N., Kudryavtsev I., Manikhas A., Musaeva N., Nizhegorodtseva A., Sadikova O., Sakaeva D., Snegovoy A., Stroyakovskiy D., Tjulandin S., Trishkina E., Vladimirova L., Volkov N., Kostalanova Y.

(Rus)

卷 25, 编号 4 (2023)

Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review

Ognerubov N.

(Rus)

卷 25, 编号 2 (2023)

The effect of hormonal contraception on the risk of breast cancer: A review

Iurova M., Mezhevitinova E., Yakushevskaya O., Rodionov V., Prilepskaya V.

(Rus)

Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study

Savelyeva M., Golubenko E., Sozaeva Z., Poddubnaya I., Korennaya V.

(Rus)

Triple-negative breast cancer: new options for systemic targeted therapy. A review

Andreev D., Zavyalov A.

(Rus)

卷 23, 编号 2 (2021)

Breast cancer immunophenotype and its relationship with haematopoiesis

Ryabchikov D., Chulkova S., Shamilov F., Chanturia N., Zheltikov S., Tupitsyn N.

(Rus)

Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

Board E.

(Rus)

卷 21, 编号 1 (2019)

Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports

Savelyeva M., Dudina I., Zaharenkova J., Ignatova A., Ryzhikova K., Sozaeva Z., Kudlay D., Perfileva O., Poddubnaya I.

(Rus)

卷 20, 编号 1 (2018)

Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin

Kolbin A., Mosikyan A., Balykina Y., Proskurin M.

(Rus)

卷 18, 编号 2 (2016)

Ignatova E., Burdaeva O., Kopp M., Kotiv B., Udovitsa D., Stroiakovskii D., Alekseev S., Sheveleva L., Khorinko A., Shapovalova I., Moiseenko V., Ivanov R.

(Rus)

卷 17, 编号 2 (2015)

Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy

Krivorotko P., Burdaeva O., Nechaeva M., Frolova M., Kopp M., Abrosimova A., Ivanov R.

卷 16, 编号 3 (2014)

Personalized approach to HER2-positive advanced breast cancertherapy

Stenina M.

卷 15, 编号 4 (2013)

Bone mineral density in patient with breast cancer

Poddubnaya I., Kizhaev E., Kolyadina I., Banov S., Zhmaeva E., Secko M.

卷 11, 编号 3 (2009)

Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy

Semiglazov V., Semiglazov V., Zhil'tsova E.

卷 11, 编号 2 (2009)

Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa

Novik A., Ionova T., Kalyadina S.

Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy

Stenina M.

卷 8, 编号 4 (2006)

Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode

Arslanov K., Tkachenko G.

卷 8, 编号 1 (2006)

Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy

Samoylenko V., Gorbunova V., Koshelev M., Yurashko K.

Faktory prognoza pri rake molochnoy zhelezy

Bozhok A., Semiglazov V., Semiglazov V., Arzumanov A., Kletsel' A.

卷 26, 编号 2 (2024)

Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review

Grechukhina K., Filonenko D., Sukhova M., Zhukova L.

(Rus)

卷 25, 编号 2 (2023)

Breast cancer: genetic personal risk factors: A review

Zolotykh M., Bilyalov A., Nesterova A., Gimranov A., Filina J., Rizvanov A., Miftakhova R.

(Rus)

卷 24, 编号 2 (2022)

Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes

Snegovoy A., Kononenko I.

(Rus)

Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021

Board E.

(Rus)

Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer

Nenahova Y., Lyadov V., Poddubnaya I.

(Rus)

The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015

Poddubnaya I., Frank G., Yagudina R., Koroleva N., Zavalishina L.

(Rus)

卷 17, 编号 2 (2015)

Stereotactic biopsy of breast lesions under x-ray control

Manikhas G., Safronova O., Khudjakova T., Barabanova L., Punanova N.

High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)

Seryakov A., Ovchinnikova L., Zabelin M., Yakubov T., Sidorov D., Ovchinnikov M.

卷 15, 编号 2 (2013)

New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer

Artamonova E., Manzyuk L.

卷 11, 编号 4 (2009)

Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy

Artamonova E.

卷 11, 编号 2 (2009)

HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy

Ognerubova I.

Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy

卷 9, 编号 2 (2007)

Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy

Semiglazov V., Semiglazov V.

Biologicheskie kharakteristiki opukholi (proliferativnaya aktivnost', ploidnost' i steroidnye retseptory) i ikh vliyanie na neposredstvennye i otdalennye rezul'taty lecheniya zapushchennogo raka molochnoy zhelezy

Nikolaeva T., Vyshinskaya G., Rotobel'skaya L.

Mammography followed by ultrasonography compared to mammography alone for breast cancer screening in women at average risk of breast cancer (Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review)

Editorial B.

(Rus)

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

Use of psychological interventions in women diagnosed and under treatment for non-metastatic breast cancer [Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review]

Mustafina F.

(Rus)

卷 23, 编号 4 (2021)

Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III

Morozov D., Kolyadina I., Poddubnaya I., Ganshina I., Khokhlova S., Kоmetova V., Rodionov V.

(Rus)

卷 23, 编号 2 (2021)

Board E.

(Rus)

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

Board E.

(Rus)